ArticleQuantitative imaging in medicine and surgery2026
Quantitative MRI mapping parameters to differentiate HER2-positive and HER2-low breast cancer.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) is the most common malignant tumor among women worldwide, and early detection and precise molecular subtyping are crucial for improving survival rates. Quantitative magnetic resonance imaging (MRI) mapping techniques have demonstrated potential in evaluating tumor tissue characteristics. The aim of this study was to evaluate the value of quantitative MRI mapping parameters in determining human epidermal growth factor receptor 2 (HER2) status in BC. Methods: In this retrospective study, 178 women with histologically confirmed BC underwent preoperative MRI, including longitudinal relaxation time (T1), transverse relaxation time (T2), and effective transverse relaxation time (T2*) mapping sequences. Following triplicate region of interest (ROI) measurements by two independent radiologists per lesion, the median value for each radiologist was calculated and then averaged between them to derive the final quantitative parameter. Quantitative mapping parameters were compared across HER2 groups with Bonferroni-adjusted tests. Multivariable regression was performed to identify independent predictors for differentiating HER2 statuses. Results: Significant differences in estrogen receptor (ER) and progesterone receptor (PR) status were observed between the HER2-low and HER2-positive groups (P Conclusions: A combined model incorporating ER state, T2* and T1_post value showed good discriminative ability in non-invasively differentiating HER2-low from HER2-positive BCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.